Rib cage stiffness goes largely unnoticed because it develops gradually. With easy daily exercises, you can restore healthy motion and relieve or prevent back pain.
Nursing a broken rib has taught me lessons about invisible illness. Like mental health concerns, these illnesses go unnoticed ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...
The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...
Male patients with newly diagnosed multiple myeloma present with more advanced disease, showing twofold higher odds for International Staging System stage III disease and greater end-organ damage than ...
Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Wiley online in CANCER, a ...
Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Wiley online in CANCER, a ...
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...
Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...
It’s not uncommon to experience random aches and pains. In most cases, the discomfort is harmless or a sign that a person has overexerted themselves, slept poorly, or spent too long in one position.
Bispecific antibody therapy could enhance multiple myeloma treatment at the community level, improving patient access to advanced care. Key challenges include logistical hurdles, such as the need for ...
In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results